A Gail score is a breast cancer risk estimate, expressed as a percentage, that predicts your chance of developing invasive breast cancer over the next five years and over your lifetime (up to age 90). It comes from the Gail Model, formally called the Breast Cancer Risk Assessment Tool, developed by the National Cancer Institute. A five-year score of 1.67% or higher is the key threshold that classifies you as having increased breast cancer risk.
How the Score Is Calculated
The Gail Model uses a combination of personal medical history, reproductive history, and family history to generate your risk percentage. The specific factors it considers include your current age, the age you got your first period, the age at which you had your first live birth (or whether you’ve given birth at all), the number of first-degree female relatives (mother, sisters, daughters) who have had breast cancer, and the number of previous breast biopsies you’ve had. Each of these factors shifts the final percentage up or down.
The tool produces two numbers: a five-year risk and a lifetime risk. Your five-year risk is the one most commonly referenced in clinical decisions, because it determines whether you cross that 1.67% threshold. For context, the average five-year risk varies by age, so the tool also shows how your score compares to the average woman of the same age and race.
What the 1.67% Threshold Means
The 1.67% cutoff isn’t arbitrary. It’s the level the FDA used when it approved preventive medications for breast cancer risk reduction. If your five-year Gail score reaches or exceeds 1.67%, you may be a candidate for risk-reducing medications that block estrogen’s effect on breast tissue. The U.S. Preventive Services Task Force recommends that women at increased risk who also have a low risk of side effects be offered these medications as an option.
Crossing the threshold doesn’t mean you will get breast cancer. A score of 2%, for example, means that out of 100 women with similar risk profiles, about two would develop invasive breast cancer within five years. The score is a statistical tool for guiding prevention decisions, not a diagnosis.
How It Guides Prevention Decisions
For women aged 35 and older whose five-year score hits 1.67%, preventive medication becomes part of the conversation. But the benefit-risk calculation isn’t the same for everyone. Research published in the Journal of Clinical Oncology found that for women aged 50 to 59 with a uterus, the benefits of one common preventive medication only clearly outweighed risks when the five-year risk reached 4.5% or higher. Below 4.0%, the side effects (including blood clots and uterine complications) actually outweighed the cancer prevention benefit.
For women without a uterus, the math shifts more favorably because certain side effects drop out of the equation. In that group, benefits outweighed risks at lower score thresholds: around 2.0% for women in their 50s, 3.0% for women in their 60s, and 4.5% for women in their 70s. Your doctor weighs your specific Gail score against your age, overall health, and personal risk tolerance before recommending any medication.
Beyond medication, a higher Gail score may also influence decisions about how often you get mammograms or whether additional screening methods are appropriate.
Who the Gail Model Works For
The tool was designed for women aged 35 and older who do not have a prior history of invasive breast cancer, ductal carcinoma in situ (DCIS), or lobular carcinoma in situ (LCIS). It also should not be used for women who carry a known genetic mutation like BRCA1 or BRCA2, or those who received radiation therapy to the chest earlier in life. For women with a BRCA mutation, the mutation itself determines risk (45% to 65% by age 70), making a Gail score irrelevant.
The model also has a notable blind spot with family history. It only counts first-degree female relatives with breast cancer. It doesn’t factor in your father’s side of the family, the age at which relatives were diagnosed, or family history of ovarian cancer. If you have an extensive family history that the Gail Model doesn’t fully capture, a more comprehensive tool like the Tyrer-Cuzick model may give a more accurate picture. That model incorporates second-degree relatives, paternal history, and other cancer types.
Accuracy Across Racial and Ethnic Groups
The original Gail Model was built primarily on data from white women, and research has shown it underestimates breast cancer risk in African American women. To address this gap, researchers developed the CARE model (Contraceptive and Reproductive Experiences model) using data from over 1,600 African American women with breast cancer and a similar number of matched controls.
The difference is significant. In one study comparing the two models in African American women, only 7% crossed the 1.67% high-risk threshold using the standard Gail Model, compared to 21% using the CARE model. The average five-year risk estimate jumped from 0.88% with the Gail Model to 1.29% with the CARE model. The National Cancer Institute’s online calculator now incorporates race-specific data, including the CARE model’s adjustments for African American women, so the version available today is more accurate across racial groups than the original.
How to Get Your Score
The National Cancer Institute hosts a free online version of the tool at bcrisktool.cancer.gov. You’ll need to know your age, race, age at first period, age at first live birth, number of first-degree relatives with breast cancer, and whether you’ve had breast biopsies (and if so, how many). The calculation takes about two minutes. While the tool is designed for use with a healthcare provider who can interpret the results in the context of your full medical history, the online version is publicly accessible and straightforward to use on your own.